Tazocin Intervention Study

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

1. To determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization and infection.

2. To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre-and post-intervention in the selected medical centers.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Piperacillin; Piperacillin, Tazobactam Drug Combination

Criteria

Inclusion Criteria:

• All patients admitted or transferred to the ICU/pulmonary/Infection units

• Patients of either sex, 18 years of age or older Patients who stay in units less than 48 hours will not be enrolled.